Casimersen (INN) (formerly known as antisense oligonucleotide nusinersen) is an antisense oligonucleotide medication used to treat spinal muscular atrophy. It is designed to alter the pre-mRNA splicing of the survival motor neuron 1 (SMN1) gene in order to increase the production of the functional SMN protein. Casimersen was approved in December 2016 in the United States and in February 2017 in the European Union.
Casimersen: A Targeted Therapy for Duchenne Muscular Dystrophy
Casimersen, sold under the brand name Amondys 45, is an antisense oligonucleotide medication used to treat a specific form of Duchenne muscular dystrophy (DMD).
What is Duchenne Muscular Dystrophy (DMD)?
DMD is a rare genetic disorder that primarily affects males and causes progressive muscle weakness. It is caused by mutations in the dystrophin gene, which leads to the absence or malfunction of the dystrophin protein. This protein is essential for muscle function, and its deficiency results in muscle degeneration and weakness.
How Does Casimersen Work?
Casimersen works through a process called exon skipping. It is designed to target a specific region (exon) of the dystrophin gene and excludes it from the mRNA production process. This allows the production of an alternative, shorter form of dystrophin protein. While not fully functional, this partially functional dystrophin protein can improve muscle function and slow down the progression of DMD.
Key Points about Casimersen:
- Indication: Approved for DMD patients with a confirmed mutation amenable to exon 45 skipping.
- Not a cure: Casimersen does not cure DMD but aims to manage the symptoms and improve muscle function.
- Administration: Administered through weekly intravenous injections by a healthcare professional.
- Potential side effects: Common side effects include fever, headache, vomiting, and injection site reactions. More serious side effects, though rare, are possible.
- Important considerations:
- Casimeren is an approved medication, but its approval is based on accelerated pathways.
- Further studies are ongoing to confirm its long-term safety and efficacy.
- It is crucial to understand that Casimeren is only effective for specific DMD mutations. Genetic testing is required to determine if a patient is eligible for treatment with Casimeren.